Kidney Diseases
The Review Journal for Research Exchange between East and West

In this Issue

· Peritoneal Dialysis
· Hemodialysis
Chronic kidney disease (CKD) is a growing worldwide public health problem resulting from the increasing number of patients with diabetes and hypertension, but also from the aging of the population. As the pathology associated with CKD appears to become more complex with age, it is essential to improve the prognosis of patients suffering from CKD by developing effective measures to prevent and control complications for the elderly.

The publication at hand makes a significant contribution to achieving this goal, with renowned Japanese scientists presenting their recent research results. Papers cover various aspects of CKD and related morbidities, ranging from dialysis- and access-related issues to bone disorders, tissue engineering, or hyperphosphatemia.

Due to the wide range of topics presented, this book will be of interest to readers in various clinical and research settings connected with the care for the elderly.

Contents

- Preface: Nitta, K.
- Clinical Effect of Pre-Dilution Hemodiafiltration Based on the Permeation of the Hemodiafilter: Yamashita, A.C.; Sakurai, K.
- The Past, Present and Future of the Dialyzer: Mineshima, M.
- Importance of Abnormal Bone Metabolism in the Acceleration of Atherosclerosis in Hemodialysis Patients: Inaba, M.
- Klotho/FGF23 Axis in CKD: Tsuchiya, K., Nagano, N.; Nitta, K.
- Cell Sheet-Based Tissue Engineering for Mesothelial Cell Injury: Kawanishi, K.; Nitta, K.
- Erythropoiesis-Stimulating Agent Hyporesponsiveness in End-Stage Renal Disease Patients: Ogawa, T.; Nitta, K.
- Past and Present Perspectives on Encapsulating Peritoneal Sclerosis: Kawanishi, H.; Shintaku, S.; Banshdani, M.; Hashimoto, Y.
- DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice: Abe, M.; Okada, K.
- Present Status and Future of Peritoneal Dialysis in Japan: Nakamoto, H.
- Cost-Effectiveness of Hemodialysis in Japan: Takura, T.
- New Aspects of Cerebrovascular Diseases in Dialysis Patients: Nagamura, T.; Takemoto, Y.
- Current Topics of Purification and Constitutions of Dialysis Fluid: Tomo, T.
- Vascular Calcification in End-Stage Renal Disease Patients: Nitta, K.; Ogawa, T.

The easiest way to order: www.karger.com/cone
Kidney Diseases

Aims and Scope

Kidney Diseases aims to provide a platform for Asian and Western research to further and support communication and exchange of knowledge. Review articles cover the most recent clinical and basic science relevant to the entire field of nephrological disorders, including glomerular diseases, acute and chronic kidney injury, tubulo-interstitial disease, hypertension and metabolism-related disorders, end-stage renal disease, and genetic kidney disease. Special articles are prepared by two authors, one from Eastern and one from West, which compares, generates, epidemiology, diagnosis methods, and treatment options of a disease. Each issue of Kidney Diseases will be devoted to a particular topic, with invited opinion leaders contributing expert review articles on the subject chosen.

Submission

The Journal accepts invited Review Articles. Manuscripts written in English should be submitted to:

S. Karger AG
Editorial Office Kidney Diseases
PO Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 15 29
Fax +41 61 306 14 34
E-mail kidderkarger.com

All manuscripts must be accompanied by a cover letter. Assurance should be given in the cover letter that the manuscript is not under simultaneous consideration by any other publication.

Invited Reviews

Invited Review Articles provide expert overviews of the latest clinical data and therapeutic regimens.

Length of Review Articles:
- max. 300 word abstract
- approx. 4,000 word main text
- 2 tables
- 3 illustrations
- approx. 50 references

Conditions

All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication, reproduction of an article for public use, or presentation of a paper at a conference implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Kidney Diseases and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Peer-Review Policy

Kidney Diseases is a peer-reviewed journal that uses a single blind peer-review. Our aim is to provide authors with fast and constructive feedback regarding their submitted manuscript. The Editor-in-Chief and the international Editorial Board ensure a thorough and fair peer-review and the highest scientific publishing standards. Submitted manuscripts are checked by the Editorial Office and forwarded to the Editor-in-Chief, who decides whether to accept/ reject or send the manuscript for review to at least two reviewers that can be members of the Editorial Board or external reviewers. Reviewers must have a recent publication record in the area of the submission, must not have published with the authors in the previous three years, and must not be from the same institution as the authors. The Editor-in-Chief makes a final decision on all papers submitted to the journal and is responsible to maintain high quality peer-review.

Conflicts of Interest

Authors are required to disclose any financial (funding, stocks, patents, employment, honoraria, royalties) or non-financial (political, personal, professional) interests/relationships that may be interpreted to have influenced the manuscript. Conflicts of Interest Statements will be published at the end of the manuscript. If there is no conflict of interest, please state The authors declare no conflicts of interest.

Ethics

Research must comply with the guidelines for human studies and animal welfare regulations. Manuscripts reporting studies on human subjects should include evidence that the research was ethically conducted in accordance with the World Medical Association Declaration of Helsinki. In particular, authors must state in Statement of Ethics at the end of the manuscript that subjects (or their parents or guardians) have given their informed written consent and that the study protocol was approved by an appropriate ethics committee. All patients should be identified by numbers or aliases, not by their real names. For clinical trials, registration in a public trials registry at or before the time of first patient enrollment is a condition of consideration for publication. The trial registration number must be provided upon submission. Authors should also state that animal experimentation was approved by the appropriate institutional review body. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

Plagiarism Policy

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

Arrangement

The manuscript should conform to the following order: title page, abstract and key words, body, acknowledgments, references, figure legends, tables and figures. Manuscripts should be written in high-quality English suitable for effective communication to a professional medical audience. For authors whose native language is not English, use of a professional language editing service (http://www.karger.com/Resources/Authors) prior to submission can help to avoid delays with the review process. All pages, including the figure legends, should be numbered in sequence, and the first author’s name should appear at the upper right corner of each page. Papers not conforming to the journal style will be returned without review.

Title page: The first page of each paper should indicate a concise title of no more than 150 characters, all authors’ names (first name and surname), authors’ institutional affiliations, and a short title for use as running head.

Corresponding author: The exact postal address of author(s) to whom corresponding, proofs, and reprint requests should be sent, including the postal code, must be given at the bottom of the title page. Please also supply phone number and e-mail address.

Abstract of Review Articles: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review. Submit the abstract on a separate page. The abstract should be less than 300 words.

Key words: Following the abstract, an alphabetical list of five key words that reflect the content of the paper should be given.

Footnotes: Avoid footnotes.

Tables and illustrations: Tables and illustrations (both numbered in sequential Arabic numerals) should be prepared as separate files. Tables require a brief and concise heading. Figures require a legend, prepared as a separate page, after references. Please use scale markers for electron micrographs, and indicate the type of stain used. For the reproduction of illustrations, only good drawings and original photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 x 223 mm) or provide crop marks. Electronically submitted b/w/half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Thoebalds TC, Boucher W, Speer K: Serum interleukin-6 reflects disease severity and osteoporosis.
in mastocytosis patients. Int Arch Allergy Immunol
DOI: 10.1159/000063858.
(c) Monographs: Matthews DE, Fare-well VT: Using
and Understanding Medical Statistics, ed 3, revised.
Basel, Karger, 1996.
(d) Edited books: DuBois RN: Cyclooxygenase-2 and
colorectal cancer; in Dannenberg AJ, DuBois RN (eds):
pp 124–137.

Reference Management Software: Use of EndNote is
recommended for easy management and formatting
of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifi-
cers for articles. A DOI number will be printed on the
title page of each article. DOIs can be useful in the fu-
ture for identifying and citing articles published online
without volume or issue information. More informa-
tion can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data
that are not necessary for the scientific integrity and
closures of the paper. Please note that all supple-
mentary files will undergo editorial review and should
be submitted together with the review article. The Edi-
tors reserve the right to limit the scope and length of
the supplementary material. Supplementary material
must meet production quality standards for Web pub-
lication without the need for any modification or edit-
ing. In general, supplementary files should not exceed
10 Mb in size. All figures and tables should have titles
and legends and all files should be supplied separately
and named clearly. Acceptable files and formats are:
Word or PDF files, Excel spreadsheets (only if the data
cannot be converted properly to a PDF file), and video
files (.mov, .avi, .mpeg).

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e.
pre-peer review) or post-prints (i.e. accepted manu-
script after peer review but before production) on their
personal or their institution’s internal website. In ad-
dition, authors may post their accepted manuscripts
in public Open Access repositories and scientific net-
works (e.g. ResearchGate or Mendeley) no earlier than
12 months following publication of the final version of
their article. For all self-archiving, the posted manus-
cripts must:
• Be used for noncommercial purposes only
• Be linked to the final version on www.karger.com
• Include the following statement:
  ‘This is the peer-reviewed but unedited manuscript
  version of the following article: [insert full citation,
e.g. Cytogenet Genome Res 2014;142:227–238 (DOI:
  10.1159/000361001)]. The final, published version is
  available at http://www.karger.com/doi=[insert DOI
  number].’
It is the author’s responsibility to fulfill these require-
ments.
For papers published online first with a DOI number
only, full citation details must be added as soon as the
paper is published in its final version. This is important
to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Pub-
lic Access Policy mandates that accepted, peer-re-
viewed manuscripts are archived in its digital data-
base, PubMed Central (PMC), within 12 months of
the official publication date. As a service to authors,
Karger submits NIH-funded articles to PMC on be-
half of the authors immediately upon publication.
The NIH assigns a PMCID within approximately
1 month and the manuscript will appear in PMC after
a 12-month embargo. For authors making their paper
Open Access through Author’s Choice™, the embargo
will be overridden, thereby accelerating the accessi-
bility of the article. Karger also complies with other
funders’ requirements (including Wellcome Trust and
RCUK) for submission to PMC. Authors should in-
clude information on their grants in the Acknowledge-
ments section of their papers.

Proofs
Unless indicated otherwise, proofs are sent to the corre-
sponding author and should be returned with the least
possible delay. Alterations other than the correction of
printer’s errors are charged to the author.

Reprints
Order forms and a price list are sent with the proofs.
Orders submitted after the issue is printed are subject
to considerably higher prices.

Guidelines for Authors
Cardiorenal Management: An Integrated Approach

Introduction

• An Integrated Approach for Cardiorenal Management: Canaud, B.; Tetta, C.; McCullough, P.A.; Chawla, L.S.
• Biomarkers in Cardiorenal Syndrome: Forni, L.G.; Chawla, L.S.
• Pharmacologic Therapies for Chronic and Acute Decompensated Heart Failure: Specific Insights on Cardiorenal Syndromes: Roubille, F.; Morena, M.; Leray-Moragues, H.; Canaud, B.; Cristol, J.-P.; Klouche, K.
• The Case for Treating Refractory Congestive Heart Failure with Ultrafiltration: Canaud, B.; Bowry, S.K.; Tetta, C.; Gatti, E.
Contents

See the journal website for contents
1st Vascular Access Scientific Meeting

Brisbane Convention and Exhibition Centre
29 - 30 April 2016
Queensland, Australia

This first dedicated Vascular Access meeting in Australia will provide an informative, thought-provoking and challenging Scientific Program and showcase the latest evidence and updates in vascular access along the continuum of care - from neonates to the elderly.

The program will include keynote presentations delivered by well respected and inspirational local and international speakers, as well as oral presentations, pre-meeting workshops and poster sessions.

This Inaugural meeting has been embraced by industry and sponsors include: Bard Access Systems, BD and CareFusion, GE Healthcare, Baxter and 3M. In addition another 12 companies have committed as exhibitors at the event.

This is a meeting no health care professional working in Vascular Access should miss!

To register or submit a presentation for consideration into the program visit the conference website:

avasasm.org.au
Where do we come from? Is our destiny determined by the genes we inherit? In this book Gottfried Schatz, the world-renowned biochemist and co-discoverer of mitochondrial DNA, gives lucid – albeit often surprising – answers to universal questions and takes the reader on a fascinating journey of discovery across the boundaries of scientific disciplines. With passion and a keen sense of wonder he draws on philosophy, cultural history and art to formulate his reflections on the mysteries of life. His essays will appeal not only to scientists but to all inquisitive minds, regardless of educational and professional background.
The American Journal of Nephrology is a peer-reviewed journal that focuses on timely topics in both basic science and clinical research. Papers are divided into several sections, including:

- Original reports, spanning clinical, basic and outcomes research
- In-depth topic reviews on specific topics selected by the Editor and Associate Editors
- Invited debates – selected on ‘hot topics’ determined by the editorial board

Responding to the ever increasing pace in research, the American Journal of Nephrology adheres to a very tight publication schedule: accepted papers appear online within 5–6 weeks of acceptance.

Selected contributions

- Meyer, C.J. (Irving, Tex.); McMurray, J.J. (Glasgow); Parving, H.-H. (Copenhagen); Pergola, P.E. (San Antonio, Tex.); Remuzzi, G. (Bologna); Toto, R.D. (Dallas, Tex.); Vaziri, N.D. (Irvine, Calif.); Wannenes, C. (Würzburg); Warnock, D.G. (Birmingham, Ala.);
- Wittere, J. (Washington, D.C.); Chertow, G.M. (Palo Alto, Calif.)
- Role of Urea in Intestinal Barrier Dysfunction and Disruption of Epithelial Tight Junction in Chronic Kidney Disease: Vaziri, N.D.; Yuan, J. (Irvine, Calif.); Norris, K. (Los Angeles, Calif.)
- Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl: Chin, M.P.; Reisman, S.A. (Irvine, Tex.); Bakris, G.L. (Chicago, Ill.); O’Grady, M. (Irving, Tex.); Linde, P.G. (North Chicago, Ill.);
- McCullough, P.A. (Dallas, Tex./Plano, Tex.); Packham, D. (Melbourne, Vic.);
- Meyer, C.J. (Irving, Tex.)
- Chlorthalidone for Poorly Controlled Hypertension in Chronic Kidney Disease: An Interventional Pilot Study: Agarwal, R.; Sinha, A.D.; Pappas, M.K.; Ammous, F. (Indianapolis, Ind.)
- Percutaneous Renal Biopsy of Native Kidneys: A Single-Center Experience of 1,055 Biopsies: Korbet, S.M.; Volpin, K.C.; Whittey, W.L. (Chicago, Ill.)

More information at www.karger.com/ajn
The fifth revised edition of this highly successful book presents the most extensive enhancement since Using and Understanding Medical Statistics was first published 30 years ago. Without question, the single greatest change has been the inclusion of source code, together with selected output, for the award-winning, open-source, statistical package known as R. This innovation has enabled the authors to de-emphasize formulae and calculations, and let software do all of the ‘heavy lifting’.

This edition also introduces readers to several graphical statistical tools, such as Q-Q plots to check normality, residual plots for multiple regression models, funnel plots to detect publication bias in a meta-analysis and Bland-Altman plots for assessing agreement in clinical measurements. New examples that better serve the expository goals have been added to a half-dozen chapters. In addition, there are new sections describing exact confidence bands for the Kaplan-Meier estimator, as well as negative binomial and zero-inflated Poisson regression models for overdispersed count data.

The end result is not only an excellent introduction to medical statistics, but also an invaluable reference for every discerning reader of medical research literature.
Peritoneal Dialysis: Reviews

147 Peritoneal Dialysis in Asia
Kwong, V.W.-K.; Li, P.K.-T. (Hong Kong)

157 Peritoneal Dialysis in Western Countries
Struijk, D.G. (Amsterdam)

Hemodialysis: Reviews

165 Hemodialysis in Asia
Prasad, N. (Lucknow); Jha, V. (Chandigarh/New Delhi)

178 Chronic Hemodialysis Therapy in the West
Rocco, M.V. (Winston-Salem, N.C.)

Reviews

187 Inflammasomes in the Pathophysiology of Kidney Diseases
Masood, H.; Che, R.; Zhang, A. (Nanjing)

194 Integrative Biology of Diabetic Kidney Disease
Harder, J.L.; Hodgin, J.B.; Kretzler, M. (Ann Arbor, Mich.)

In the Upcoming Issues
- Vasculitis
- Multiple Myeloma